ACM
RARE icon

Aster Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Aster Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.7K Sell
573
-1,870
-77% -$42.1K 0.01% 549
2025
Q4 		$56.2K Buy
+2,443
New +$80.3K 0.02% 445
2025
Q1 		– Sell
-825
Closed -$34.7K – 1603
2024
Q4 		$34.7K Buy
+825
New +$40.9K 0.01% 549

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Aster Capital Management's RARE Position: Q1 2026 in Review

Aster Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 77% in Q1 2026, selling an estimated $42.1K and leaving 573 shares worth $20.7K. The position accounts for 0.01% of the portfolio, ranked #549.

Aster Capital Management first reported a position in RARE in Q4 2024 and has held it in 3 quarters since. The position peaked at $56.2K in Q4 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Aster Capital Management held 573 shares of Ultragenyx Pharmaceutical worth $20.7K as of Q1 2026.
  • Aster Capital Management sold 1,870 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $42.1K.
  • Ultragenyx Pharmaceutical made up 0.01% of Aster Capital Management's portfolio in Q1 2026, its #549 holding.
  • Aster Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 3 quarters since.
  • Aster Capital Management's Ultragenyx Pharmaceutical position peaked at $56.2K in Q4 2025.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.